Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | FIIN-2 |
Synonyms | |
Therapy Description |
FIIN-2 is a selective, irreversible Fgfr inhibitor that can inhibits Fgfr mutants that confer resistance to first-generation Fgfr inhibitors, resulting in growth inhibition in tumor cells (PMID: 25349422). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FIIN-2 | FGFR Inhibitor (Pan) 18 | FIIN-2 is a selective, irreversible Fgfr inhibitor that can inhibits Fgfr mutants that confer resistance to first-generation Fgfr inhibitors, resulting in growth inhibition in tumor cells (PMID: 25349422). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR3 N540K | Advanced Solid Tumor | decreased response | FIIN-2 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to FIIN-2 in culture (PMID: 28034880). | 28034880 |
FGFR3 L608V | Advanced Solid Tumor | sensitive | FIIN-2 | Preclinical - Cell culture | Actionable | In a preclinical study, FIIN-2 inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880). | 28034880 |
FGFR3 V555M | Advanced Solid Tumor | decreased response | FIIN-2 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing FGFR3 V555M demonstrated reduced sensitivity to FIIN-2 in culture (PMID: 28034880). | 28034880 |
FGFR3 K650E | Advanced Solid Tumor | sensitive | FIIN-2 | Preclinical - Cell culture | Actionable | In a preclinical study, FIIN-2 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880). | 28034880 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|